Antarctic Krill Oil Functional Food Mitigates Bladder Cancer Treatment Side Effects

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Mar 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether Antarctic krill oil can help reduce the side effects of a specific bladder cancer treatment called intravesical therapy. This therapy involves putting medication directly into the bladder. The trial will involve 210 participants aged 18 to 75 who have been diagnosed with non-muscle-invasive bladder cancer and are planning to receive this treatment. Participants will be randomly assigned to either take krill oil capsules daily or a placebo (a non-active treatment) during their therapy.

To be eligible for the trial, participants must have normal blood, liver, and kidney function and must agree to join the study by signing a consent form. They should not have serious health issues, a history of allergies to krill oil, or other recent cancer treatments. Throughout the trial, researchers will monitor how well the krill oil works in reducing symptoms like bladder irritation and any side effects from the treatment. The goal is to find out if this dietary supplement can improve the quality of life for bladder cancer patients during their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosed bladder cancer: The patient needs to be diagnosed with bladder cancer through pathological examination and have undergone bladder cancer surgery.
• • 2. Planned to receive bladder infusion therapy: Patients need to plan to receive bladder infusion therapy after surgery and agree to participate in the study.
• • 3. Age range: 18 to 75 years old.
• • 4. Normal blood, liver and kidney function: Laboratory tests showed that the patient's blood routine, liver function and kidney function were within the normal range.
• • 5. Signed informed consent: The patient understands the content of the study and voluntarily signs the informed consent.
• Exclusion Criteria:
• • 1. Serious comorbidities: including but not limited to heart disease, severe liver and kidney insufficiency, uncontrolled hypertension, diabetes, etc.
• • 2. History of allergies: Patients with a known history of allergy to krill oil or perfusion drug components.
• • 3. History of prior chemotherapy: Patients who have received perfusion therapy prior to this study.
• • 4. History of other malignant tumors: Patients with a history of other malignant tumors.
• • 5. Pregnancy or lactation: Female patients who are pregnant or lactating.
• • 6. Psychiatric illness: Patients with a history of severe psychiatric illness or currently receiving treatment for psychiatric illness.
• • 7. Poor study compliance: Patients who believe that they are unable to complete the entire trial process as required by the study.
• • 8. Other: Other conditions that the investigator considers unsuitable to participate in this study.